ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: SA-PO816

Link between Iron Deficiency and Thrombocytosis in Dialysis Patients – Are ADPKD Patients Different?

Session Information

Category: Dialysis

  • 605 Dialysis: Anemia and Iron Metabolism

Authors

  • Nadrowitz, Felix, Hannover Medical School, Hannover, Germany
  • Stahl, Klaus, MHH, Hannover, Germany
  • Schmidt, Bernhard M.W., Hannover Medical School, Hannover, Germany
  • von Gersdorff, Gero D., University Hospital Cologne, Cologne, Germany
  • Rascher, Katherine, University Hospital Cologne, Cologne, Germany
  • Haller, Hermann G., Hannover Medical School, Hannover, Germany
  • Schmitt, Roland, Medizinische Hochschule Hannover, Hannover, NI, Germany
Background

Secondary thrombocytosis has been reported in iron deficiency (ID) anemia. Maintenance hemodialysis (MHD) patients with adult polycystic kidney disease (ADPKD) often receive low iron supplementation due to their spontaneously high hemoglobin levels. We analyzed a possible correlation between ID and platelet count in MHD ADPKD and non-ADPKD patients.

Methods

We conducted a multi-center cohort study with 2387 ADPKD and 30923 non-ADPKD patients. Data between 2008 and 2015 were extracted from over 190 outpatient hemodialysis centers from the institutional KfH quality registry. Multivariable correlation as well as multivariable linear regression analysis with thrombocyte count and parameters of iron status were performed. To correct for inflammation dependent changes laboratory measurements were only included when CRP was in the normal range.

Results

While mean transferrin saturation (TSAT) in ADPKD patients indicated ID (16.6 ± 7.4 %), mean ferritin was not in the ID range (544.8 ± 416.9 ng/ml). Mean absolute thrombocyte count in the ADPKD cohort was 202.2 ± 65.0 x103/µl. A correlation coefficient of -0.12859 implicated a statistically significant, but minor negative correlation of thrombocytes with TSAT. In non-ADPKD MHD patients mean TSAT was 17.9 ± 9.6 % and mean ferritin was 631.6 ± 446.2 ng/ml. Mean platelet count was 216.5 ± 73.7 x103/µl with a likewise significant, but small negative correlation coefficient to TSAT (-0.11974). Only an extremely low TSAT (< 2%) was associated with platelet counts above the upper limit of normal.

Conclusion

In MHD patients with ADPKD we could not find a relevant correlation of TSAT and platelet count. This was not different from non-ADPKD patients. Our study demonstrates that common degrees of ID in ADPKD and non-ADPKD patients on MHD do not result in thrombocytosis.